Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy

Hien, Tran Thi LU ; Ambite, Ines LU orcid ; Wan, Murphy Lam Yim LU ; Cavalera, Michele LU ; Esmaeili, Parisa LU ; Chaudhuri, Arunima LU orcid ; Sabari, Samudra LU ; Babjuk, Marek and Svanborg, Catharina LU (2023) In International Journal of Cancer 153(3). p.584-599
Abstract

Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin... (More)

Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
alpha1-oleate, bladder cancer, combination therapy, Epirubicin, long-term effects
in
International Journal of Cancer
volume
153
issue
3
pages
16 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:36891980
  • scopus:85152019555
ISSN
0020-7136
DOI
10.1002/ijc.34500
language
English
LU publication?
yes
id
ee4f0211-e288-471d-a4f6-6878b9c1aed3
date added to LUP
2023-07-20 10:33:32
date last changed
2025-06-29 16:33:18
@article{ee4f0211-e288-471d-a4f6-6878b9c1aed3,
  abstract     = {{<p>Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.</p>}},
  author       = {{Hien, Tran Thi and Ambite, Ines and Wan, Murphy Lam Yim and Cavalera, Michele and Esmaeili, Parisa and Chaudhuri, Arunima and Sabari, Samudra and Babjuk, Marek and Svanborg, Catharina}},
  issn         = {{0020-7136}},
  keywords     = {{alpha1-oleate; bladder cancer; combination therapy; Epirubicin; long-term effects}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{584--599}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{International Journal of Cancer}},
  title        = {{Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy}},
  url          = {{http://dx.doi.org/10.1002/ijc.34500}},
  doi          = {{10.1002/ijc.34500}},
  volume       = {{153}},
  year         = {{2023}},
}